Effect of lithium on HIV-1 expression and proviral reservoir size in the CD4+ T cells of antiretroviral therapy suppressed patients

AIDS

Volumn 28, Issue 14, 2014, Pages 2157-2159

  Puertas, Maria C ^a   Salgado, Maria ^a   López, Sara Morón ^a   Ouchi, Dan ^a   Muñoz Moreno, Jose A ^b   Moltó, José ^b   Clotet, Bonaventura ^a,b,c   Martinez Picado, Javier ^a,c,d  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c UNIVERSITY OF VIC CENTRAL UNIVERSITY OF CATALONIA   (Spain)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BETA CATENIN; CD4 ANTIGEN; LITHIUM CARBONATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LINOLENIC ACID; LITHIUM DERIVATIVE; VIRUS DNA;

ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; DRUG DOSE TITRATION; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOMODULATION; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROVIRUS; SIGNAL TRANSDUCTION; VIREMIA; VIRUS EXPRESSION; VIRUS INHIBITION; VIRUS LATENCY; DRUG EFFECTS; GENETICS; HIV INFECTIONS; IMMUNOLOGY; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; BETA CATENIN; DNA, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; LINOLENIC ACIDS; LITHIUM COMPOUNDS; PROVIRUSES; SIGNAL TRANSDUCTION; VIRAL LOAD; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84906771318     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000374     Document Type: Article

References (15)

1. Katlama C, Deeks SG, Autran B, Martinez-Picado J, van Lunzen J, Rouzioux C, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013; 381: 2109-2117.
2. Kumar A, Zloza A, Moon RT, Watts J, Tenorio AR, Al-Harthi L. Active beta-catenin signaling is an inhibitory pathway for human immunodeficiency virus replication in peripheral blood mononuclear cells. J Virol 2008; 82: 2813-2820.
3. Henderson LJ, Narasipura SD, Adarichev V, Kashanchi F, Al-Harthi L. Identification of novel T cell factor 4 (TCF-4) binding sites on the HIV long terminal repeat which associate with TCF-4, beta-catenin, and SMAR1 to repress HIV transcription. J Virol 2012; 86: 9495-9503.
4. Rafati H, LeMasters E, Lennert VDD, El-Sayyed M, Boucher C, Vries R, et al. Activation of the Wnt pathway by natural ligands or small molecule inhibitors activates latent HIV. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 30 June to 3 July 2013; Kuala Lumpur, Malaysia.
5. Letendre SL, Woods SP, Ellis RJ, Atkinson JH, Masliah E, van den Brande G, et al. Lithium improves HIV-Associated neurocognitive impairment. AIDS 2006; 20: 1885-1888.
6. Schifitto G, Zhong J, Gill D, Peterson DR, Gaugh MD, Zhu T, et al. Lithium therapy for human immunodeficiency virus type 1-Associated neurocognitive impairment. J Neurovirol 2009; 15: 176-186.
7. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487: 482-485.
8. Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16: 460-465.
9. Siliciano JD, Siliciano RF. Enhanced culture assay for detection and quantitation of latently infected, resting CD4R T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol 2005; 304: 3-15.
10. Prado JG, Prendergast A, Thobakgale C, Molina C, Tudor-Williams G, Ndung'u T, et al. Replicative capacity of human immunodeficiency virus type 1 transmitted from mother to child is associated with pediatric disease progression rate. J Virol 2010; 84: 492-502.
11. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15: 893-900.
12. Yukl SA, Shergill AK, Ho T, Killian M, Girling V, Epling L, et al. The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence. J Infect Dis 2013; 208: 1212-1220.
13. Kulpa DA, Brehm JH, Fromentin R, Cooper A, Cooper C, Ahlers J, et al. The immunological synapse: the gateway to the HIV reservoir. Immunol Rev 2013; 254: 305-325.
14. Rasmussen T, Tolstrup M, Brinkmann C, Olesen R, Erikstrup C, Solomon A, et al. Cyclic dosing of panobinostat to reverse HIVlatency: findings from a clinical trial. 6th International Workshop on HIV Persistence During Therapy. 3-6 December 2013, Miami, FL, USA. IHL Press; 2013. pp. 57.
15. Archin NM, Bateson R, Tripathy MK, Crooks AM, Yang KH, Dahl NP, et al. HIV-1 expression within resting CD4R T cells after multiple doses of vorinostat. J Infect Dis 2014; [Epub ahead of print].